Pharmafile Logo
Pharmafocus logo
Advanced Search
pfizer-building-logo1web

Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials

March 21, 2016
Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …

News
janssen_stairs_1

J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease

March 18, 2016
Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease

Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …

News
abraxane0058

Wales approve pancreatic cancer drug for use despite NICE rejection in England

March 18, 2016
Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval

Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …

News

Study data supports switch to Celltrion’s Remicade biosimilar

March 18, 2016
Research and Development

Celltrion and distribution partner Mundipharma have presented study data supporting switching irritable bowel disease (IBD) patients from Remicade to biosimilar …

News
shutterstock_92671375

Indian govt set to ban 1,200 fixed-dose combination drugs, reports

March 18, 2016
Business Services, Medical Communications, Sales and Marketing Abbott Laboratories, Pfizer, cough drug, pharma

Indian regulators are set to ban an additional 1,200 fixed-dose combinations, sent for probe by Drug Controller General of India …

News
clinical_trial-web

OncoMed initiates Phase Ib immuno-oncology combination clinical trial

March 18, 2016
Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib

OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …

News
allergan

Allergan files ANDA for generic version of Celgene’s breast cancer treatment

March 18, 2016
Business Services, Medical Communications, Sales and Marketing Abraxane, Allergan, Celgene, breast cancer, generic

Allergan (NYSE: AGN) said it is seeking regulatory approval for a generic version of biotech firm Celgene’s (Nasdaq: CELG) breast …

News
zydelig_gilead

Gilead cancer boss departs after safety concerns halt Zydelig trials

March 18, 2016
Medical Communications, Research and Development Gilead Sciences, zydelig

In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …

News

Kite Pharma, Roche to co-develop two new treatments for non-hodgkin lymphoma

March 18, 2016
Medical Communications, Research and Development Gentech, Roche, kite pharma, non-Hodgkin lymphoma

Kite Pharma (Nasdaq: KITE) said it will collaborate with Swiss drug major Roche (SIX: ROG) to evaluate the safety and efficacy …

News
breckenridge_pharma

FDA approves Breckenridge’s generic of Pfizer’s anti-epilepsy drug

March 18, 2016
Research and Development, Sales and Marketing FDA, Neurontin, Pfizer, anti-epilepsy, approval, breckenridge, gabapentin, tris pharma

Breckenridge Pharmaceutical Inc. has announced that their generic of Pfizer’s anti-epilepsy drug Neurontin (gabapentin) has been approved by the US …

News
msd

Merck & Co says study shows significantly higher persistence for its arthritis drug Simponi

March 17, 2016
Research and Development, Sales and Marketing Merck & Co, drug trial, research, rheumatoid arthritis

US pharma giant Merck & Co (NYSE: MRK) said its rheumatoid arthritis drug showed significantly higher persistence compared with other drugs …

News
shutterstock_95714119

Vitae Pharma soars on positive mid-stage trial results for psoriasis drug

March 17, 2016
Business Services, Research and Development, Sales and Marketing Vitae Pharmaceuticals, drug trial, psoriasis, research

Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported mid-stage trials of its psoriasis …

News

Building trust and loyalty in medical communications – London-based agency reveal their approach

March 17, 2016
Medical Communications Synergy Vision, graduate recruitment, medical communications, medical communications agency, recruitment, retention

There has always been a high turnover of staff within the medical communications industry – a recent survey on the …

News
Press release
alm_v2

Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million

March 17, 2016
Business Services, Sales and Marketing Almirall, Grünenthal Group, merger and acquisition

Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to …

News
bayercross3

FDA approves Bayer haemophilia A drug Kovaltry

March 17, 2016
Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound

Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …

News
amgen_sign_on_wall

Amgen wins high-profile cholesterol drug patent case v Sanofi

March 17, 2016
Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent

A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …

News
chugai_pharmaceutical

Chugai receive orphan drug status for autoimmune disease treatment

March 17, 2016
Manufacturing and Production, Medical Communications, Research and Development chuagi, systemic scleroderma, tocilizumab

Chugai Pharmaceutical Co. (TYO: 4519) has received a notification of orphan drug designation, from the Japanese minister of health, labour …

News
7-0_careers_taleobanner_900x600

Baxter to cut stake in Baxalta

March 17, 2016
Business Services, Sales and Marketing Baxalta, Shares, Stake sale, baxter

Baxalta Inc (NYSE: BXLT) said former parent company Baxter International (NYSE: BAX) is set to cut its stake in the …

News

Sir Andrew Witty announces decision to step down as CEO of GSK

March 17, 2016
Medical Communications, Research and Development Andrew Witty, GSK, GlaxoSmithKline, Neil Woodford, Sir Andrew Witty, Witty, gsk break up, gsk split, retirement, steps down

Sir Andrew Witty has announced his decision to retire from his role as chief executive officer of pharmaceutical giant, GlaxoSmithKline …

News
gsk_sign_good

GSK’s asthma drug meets primary goal in safety study for children

March 17, 2016
Research and Development Advair Diskus, GSK, asthma, drug trial

GlaxoSmithKline (LSE: GSK) said on Thursday its asthma drug met the primary end point in a second study for children. …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026